GZMB

Across TCGA pan-cancer cohorts, GZMB mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GZMB data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GZMB mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GZMB expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where GZMB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.176	0.740	<.001	22	view →
LSCC	DFS	Median	All	0.937	0.567	.006	5	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.258	.027	2	view →
HNSC	DFS	Quartile	All	0.894	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GZMB–PDAC (OS)

Open the PDAC breakdown →